Sound Blade Medical
Series A in 2025
Sound Blade Medical is an early-stage medical device company that specializes in developing innovative, non-invasive therapies using endoscopic histotripsy. This technology employs focused ultrasound, guided by real-time imaging, to precisely destroy targeted tissue without heat, ionizing radiation, or surgical invasion. The company aims to revolutionize healthcare by enhancing endoscopic procedures, offering a more precise and safer alternative to traditional treatments.
ShiraTronics
Series B in 2024
ShiraTronics develops neuromodulation therapies to treat chronic migraine by delivering continuous stimulation to targeted nerves to relieve, interrupt, and prevent migraine episodes. Founded in 2018 and based in Ireland, the company maintains an additional location in Minneapolis, Minnesota, and pursues innovative neuromodulation technology to address unmet neurological needs and improve patient outcomes.
HistoSonics
Series D in 2024
HistoSonics develops a non-invasive tumor ablation system called Edison. This platform uses pulsed sound energy to destroy targeted tissues at the sub-cellular level without requiring incisions or needles.
Synergy Disc Replacement
Series A in 2024
Synergy Disc Replacement is a medical device company that develops and produces cervical disc implants intended to restore balance, range of motion, and alignment of the cervical spine.
Gynesonics
Venture Round in 2023
Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.
Miach Orthopaedics
Series B in 2023
Miach Orthopaedics is a medical device company based in Westborough, Massachusetts, specializing in the development of bio-engineered surgical implants aimed at promoting new tissue growth and aiding in connective tissue repair. Founded in 2016, the company focuses on its innovative Bridge-Enhanced ACL Repair technology, which serves as an alternative to traditional anterior cruciate ligament (ACL) reconstruction. This technology provides surgeons with a method to restore the normal anatomy and function of the knee for patients who have experienced ACL injuries, offering a promising option for recovery and rehabilitation.
Thryv Therapeutics
Series A in 2021
Thryv Therapeutics is a precision medicine company focused on developing innovative therapeutics for Long QT Syndrome and other arrhythmias. The company employs a precision medicine approach to address both genetic and drug-induced long QT syndrome, as well as atrial fibrillation and treatment-resistant cancers. Thryv Therapeutics specializes in creating potent and selective inhibitors of Serum Glucocorticoid Inducible Kinase, aiming to provide therapies that can significantly reduce the risk of sudden cardiac death and enhance the quality of life for patients affected by these serious conditions.
Neuros Medical
Series B in 2021
Neuros Medical, Inc. is a neuromodulation company dedicated to developing innovative therapies to address unmet medical needs for patients globally. Founded in 2008 and headquartered in Willoughby Hills, Ohio, the company specializes in its proprietary platform technology known as Electrical Nerve Block. This technology is designed to eliminate chronic pain across various conditions, including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine. The Neuros Altius System, one of its key products, includes an implantable generator with an integrated rechargeable battery, a cuff electrode, and external devices, further demonstrating the company's commitment to advancing pain management solutions.
Reneo Pharmaceuticals
Series B in 2020
Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in San Diego, California, dedicated to developing therapies for patients with rare genetic mitochondrial diseases. These conditions are characterized by deficits in cellular metabolism and energy production, often leading to significant health challenges. The company is focused on creating treatments that improve mitochondrial function, preserve muscle integrity, and enhance the overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes critical to the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. Founded in 2014, Reneo aims to address the unmet needs of patients suffering from orphan metabolic diseases linked to mitochondrial dysfunction.
Monte Rosa Therapeutics
Series B in 2020
Monte Rosa Therapeutics is a biotechnology company focused on cancer therapeutics that target protein degradation pathways. It specializes in developing molecular glue degraders, a class of small molecules that direct disease-relevant proteins to degradation by the cell's natural machinery. The company uses its QuEEN platform, incorporating artificial intelligence and proprietary experimental tools, to identify target proteins for degradation by molecular glue degraders. It maintains a diverse library of more than 50,000 molecules and advancing its pipeline, including MRT-2359, a candidate that targets the translation termination factor GSPT1 for potential use in MYC-driven tumors.
Impulse Dynamics
Series D in 2019
Impulse Dynamics N.V. is a medical device company that specializes in developing innovative electrical therapies for chronic heart failure. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, with product development centers located in New Jersey and Israel. Its primary offering, the CCM® therapy, utilizes cardiac contractility modulation technology to deliver non-excitatory electrical impulses to the heart, enhancing its contraction and improving blood flow to the body. This minimally invasive treatment option addresses the needs of heart failure patients who have limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for ongoing research and development.
ShiraTronics
Series A in 2019
ShiraTronics develops neuromodulation therapies to treat chronic migraine by delivering continuous stimulation to targeted nerves to relieve, interrupt, and prevent migraine episodes. Founded in 2018 and based in Ireland, the company maintains an additional location in Minneapolis, Minnesota, and pursues innovative neuromodulation technology to address unmet neurological needs and improve patient outcomes.
Bellus Health
Post in 2018
Bellus Health is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare diseases, with a particular focus on conditions affecting the kidneys. Its lead drug candidate, KIACTA™, is designed for the treatment of AA amyloidosis, a rare condition that can result in severe renal dysfunction. Following the successful completion of a Phase 3 study, the company is collaborating with Auven Therapeutics to advance KIACTA™, which is also being explored for treating sarcoidosis, an inflammatory disease affecting the lungs. Additionally, Bellus Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome, a serious condition linked to Shiga toxin-producing E. coli, which poses significant health risks, especially for children. The company's research pipeline also includes efforts to address AL amyloidosis, another rare disease characterized by the accumulation of amyloid proteins in the body. Bellus Health aims to meet the high unmet medical needs of patients suffering from these conditions through its focused therapeutic developments.
Miach Orthopaedics
Series A in 2018
Miach Orthopaedics is a medical device company based in Westborough, Massachusetts, specializing in the development of bio-engineered surgical implants aimed at promoting new tissue growth and aiding in connective tissue repair. Founded in 2016, the company focuses on its innovative Bridge-Enhanced ACL Repair technology, which serves as an alternative to traditional anterior cruciate ligament (ACL) reconstruction. This technology provides surgeons with a method to restore the normal anatomy and function of the knee for patients who have experienced ACL injuries, offering a promising option for recovery and rehabilitation.
MEI Pharma is a biopharmaceutical company focused on developing novel therapies for cancer. Its pipeline includes Zandelisib (PI3K inhibitor) and Voruciclib (CDK9 inhibitor), both in clinical trials, as well as Pracinostat (HDAC inhibitor). The company collaborates with other pharmaceutical companies for drug development.
Eidos Therapeutics
Series B in 2018
Eidos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California, specializing in the development of therapies for diseases associated with transthyretin (TTR) amyloidosis (ATTR). Founded in 2013, the company is advancing its lead candidate, AG10, which is currently undergoing phase 3 clinical trials. AG10 is an orally administered small molecule designed to stabilize tetrameric TTR, aiming to interrupt the pathological processes that lead to ATTR. As a subsidiary of BridgeBio Pharma, Eidos Therapeutics is committed to addressing the clinical needs related to TTR and amyloidosis through innovative, genetically targeted therapies.
GTx, Inc. was a biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for stress urinary incontinence and prostate cancer. The company specialized in selective androgen receptor modulators (SARMs) and selective androgen receptor degraders. Its notable product candidate, enobosarm (GTx-024), was in Phase II clinical trials aimed at treating various forms of breast cancer and offering solutions for postmenopausal women with stress urinary incontinence. Founded in 1997 and based in Memphis, Tennessee, GTx aimed to improve patient outcomes through its targeted therapeutic approaches. In 2019, GTx was acquired by Oncternal Therapeutics, marking the completion of a reverse merger transaction.
Inspire Medical Systems
Series F in 2016
Inspire Medical Systems, Inc. is a medical technology company dedicated to developing and commercializing minimally invasive solutions for patients suffering from obstructive sleep apnea (OSA). Founded in 2007 and headquartered in Golden Valley, Minnesota, the company specializes in innovative implantable neurostimulation technologies. Its primary product, the Inspire system, utilizes a proprietary Upper Airway Stimulation (UAS) therapy that provides a safe and effective treatment for moderate to severe OSA. This technology leverages established principles from cardiac pacing and neurostimulation to deliver mild hypoglossal nerve stimulation, which helps maintain an open airway by continuously monitoring the patient's breathing. Inspire Medical Systems operates primarily in the United States and Europe, generating most of its revenue from the U.S. market.
Essential Medical
Series B in 2016
Essential Medical, Inc. is a medical device company based in Malvern, Pennsylvania, that specializes in the development and marketing of femoral artery vascular closure devices. Founded in 2010, the company focuses on sealing femoral punctures that occur after diagnostic and interventional cardiac catheterization procedures. Essential Medical has developed two key devices, including MANTA, which is designed to close large bore punctures ranging from 10 to 24 French following various vascular access procedures such as transcatheter aortic valve replacement, abdominal aortic aneurysm repair, and balloon aortic valvuloplasty. These closures are critical in the rapidly growing field of interventional cardiology, enabling physicians to address the need for efficient and complication-free closure solutions. As of October 2018, Essential Medical operates as a subsidiary of Teleflex Incorporated.
Assurance Operations Corp.
Acquisition in 2015
Assurance Operations Corp. is a comprehensive engineering and manufacturing firm that focuses on custom metal fabrication and stamping. The company excels in designing, developing, testing, and managing programs for custom industrial packaging and material handling solutions. Assurance Operations Corp. produces a wide range of parts, including both light and heavy components made from aluminum, stainless steel, and steel, catering to various industrial needs.
KEW, Inc., established in 2009 and headquartered in Cambridge, Massachusetts, specializes in genomic testing services for cancer patients. The company's core offering, CANCERPLEX, is a precision medicine service that analyzes a patient's genetic drivers to help oncologists select personalized, targeted therapies. KEW's suite of products includes CANCERPLEX FP, a full panel test with immunotherapy options, CANCERPLEX TS for common tumor sites, and CANCERPLEX TX for FDA-approved targeted therapies. The company delivers these solutions through strategic partnerships and distributors, enabling evidence-driven treatment decisions in cancer care.
Marbles: The Brain Store
Private Equity Round in 2014
Marbles operates a retail store offering an assortment of games, puzzles, books, and software designed to enhance cognitive abilities. It provides a hands-on shopping experience for families, featuring product demonstrations both in-store and online.